信铭生命科技中期报告 2021/22

CONTENTS 目錄Corporate Information2公司資料Management Discussion and Analysis5管理層討論及分析Disclosure of Interests18權益披露Corporate Governance23企業管治Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income25簡明綜合損益及其他全面收益表Condensed Consolidated Statement of Financial Position27簡明綜合財務狀況報表Condensed Consolidated Statement of Changes in Equity30簡明綜合權益變動表Condensed Consolidated Statement of Cash Flows32簡明綜合現金流量表Notes to the Condensed Consolidated Financial Statements33簡明綜合財務報表附註 2Interim Report 中期報告 2021/22CORPORATE INFORMATION公司資料Aceso Life Science Group Limited • 信銘生命科技集團有限公司EXECUTIVE DIRECTORSMr. Xu HaiyingDr. Zhiliang Ou, J.P. (Australia)Mr. Fok Chi TakNON-EXECUTIVE DIRECTORSDr. Wang Yu (resigned on 15 October 2021)Dr. Li Yao (resigned on 30 June 2021)INDEPENDENT NON-EXECUTIVE DIRECTORSMr. Chan Ming Sun JonathanMr. Lam Kwan SingMr. Mak Yiu Tong (appointed on 12 July 2021)Mr. Lee Chi Hwa Joshua (resigned on 12 July 2021)AUDIT COMMITTEEMr. Chan Ming Sun Jonathan (Chairman of Committee)Mr. Lam Kwan SingMr. Mak Yiu Tong (appointed on 12 July 2021)Mr. Lee Chi Hwa Joshua (resigned on 12 July 2021)EXECUTIVE COMMITTEEMr. Xu HaiyingDr. Zhiliang Ou, J.P. (Australia)Mr. Fok Chi TakREMUNERATION COMMITTEEMr. Chan Ming Sun Jonathan (Chairman of Committee)Dr. Zhiliang Ou, J.P. (Australia)Mr. Lam Kwan SingNOMINATION COMMITTEEDr. Zhiliang Ou, J.P. (Australia) (Chairman of Committee)Mr. Chan Ming Sun JonathanMr. Lam Kwan Sing執行董事許海鷹先生歐志亮博士，太平紳士（澳 洲）霍志德先生非執行董事王宇博士（於 二零二一年十月十五日辭任）李耀博士（於 二零二一年六月三十日辭任）獨立非執行董事陳銘燊先生林君誠先生麥耀棠先生（於 二零二一年七月十二日獲委任）李智華先生（於 二零二一年七月十二日辭任）審核委員會陳銘燊先生（委 員會主席）林君誠先生麥耀棠先生（於 二零二一年七月十二日獲委任）李智華先生（於 二零二一年七月十二日辭任）執行委員會許海鷹先生歐志亮博士，太平紳士（澳 洲）霍志德先生薪酬委員會陳銘燊先生（委 員會主席）歐志亮博士，太平紳士（澳 洲）林君誠先生提名委員會歐志亮博士，太平紳士（澳 洲）（委 員會主席）陳銘燊先生林君誠先生 3Interim Report 中期報告 2021/22CORPORATE INFORMATION公司資料Aceso Life Science Group Limited • 信銘生命科技集團有限公司AUTHORISED REPRESENTATIVESMr. Fok Chi TakDr. Zhiliang Ou, J.P. (Australia)COMPANY SECRETARYMs. Chan Lai PingLEGAL ADVISERRaymond Siu & LawyersAUDITORZHONGHUI ANDA CPA LimitedCertified Public AccountantsPRINCIPAL BANKERSShanghai Commercial Bank LimitedBank of China (Hong Kong) LimitedThe Hongkong and Shanghai Banking Corporation LimitedNanyang Commercial Bank, Ltd.The Bank of East Asia LimitedPRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE IN CAYMAN ISLANDSSuntera (Cayman) LimitedSuite 3204, Unit 2A, Block 3, Building DP.O. Box 1586, Gardenia CourtCamana BayGrand Cayman, KY1-1100Cayman IslandsHONG KONG BRANCH SHARE REGISTRAR AND TRANSFER OFFICEComputershare Hong Kong Investor Services LimitedShops 1712–171617th Floor, Hopewell Centre183 Queen’s Road East, Wan ChaiHong Kong授權代表霍志德先生歐志亮博士，太平紳士（澳 洲）公司秘書陳麗平女士法律顧問蕭鎮邦律師行核數師中匯安達會計師事務所有限公司執業會計師主要往來銀行上海商業銀行有限公司中國銀行（香 港） 有限公司香港上海滙豐銀行有限公司南洋商業銀行有限公司東亞銀行有限公司開曼群島主要股份過戶登記處Suntera (Cayman) LimitedSuite 3204, Unit 2A, Block 3, Building DP.O. Box 1586, Gardenia CourtCamana BayGrand Cayman, KY1-1100Cayman Islands香港股份過戶登記分處香港中央證券登記有限公司香港灣仔皇后大道東183號合和中心17樓1712–1716號舖 4Interim Report 中期報告 2021/22CORPORATE INFORMATION公司資料Aceso Life Science Group Limited • 信銘生命科技集團有限公司註冊辦事處Cricket SquareHutchins DriveP. O. Box 2681Grand Cayman KY1-1111Cayman Islands香港主要營業地點香港灣仔港灣道6–8號瑞安中心25樓2501–2509室股份代號474網址www.acesogrouphk.comREGISTERED OFFICECricket SquareHutchins DriveP. O. Box 2681Grand Cayman KY1-1111Cayman IslandsPRINCIPAL PLACE OF BUSINESS IN HONG KONGRooms 2501–2509, 25/FShui On Centre6–8 Harbour Road, WanchaiHong KongSTOCK CODE474WEBSITEwww.acesogrouphk.com 5Interim Report 中期報告 2021/22MANAGEMENT DISCUSSION AND ANALYSIS管理層討論及分析Aceso Life Science Group Limited • 信銘生命科技集團有限公司The board (the “Board”) of directors (the “Directors”) of Aceso Life Science Group Limited (the “Company”) is pleased to present the shareholders of the Company (the “Shareholders”) the interim report of the Company and its subsidiaries (the “Group”) for the six months ended on 30 September 2021 (the “Period”).BUSINESS REVIEWImpact of COVID-19During the period under review, the COVID-19 pandemic remained challenging due to the outbreak of the mutant variants. The Group remained resilient and focused on its existing businesses. Though operations of the construction industry in Hong Kong have been affected as a consequence of COVID-19, due to the relatively stable undertaking of government infrastructure projects, the Group managed to record an increase in rental income generated from construction machinery during the Period. The occupancy rate for the rental machineries was approximately 80%.For our investment property in the United Kingdom (the “UK”), 55 Mark Lane, the Group managed to lease out all upper levels of the property which are for office use.To manage the impact of COVID-19, the Group maintained its operation and put in place precautionary and risk mitigation measures, including suitably deploying remote work arrangements, periodic deep cleaning and sanitisation for both our warehouse and